AEZS - Aeterna Zentaris in-licenses targeted immunosuppressive therapeutics for rare CNS disorder

Aeterna Zentaris (AEZS) +5.3% has licensed the exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific, autoimmunity modifying proteins (“AIM Biologicals”) for the potential treatment of neuromyelitis optica spectrum disorder ((NMOSD)), from the Julius-Maximilians-University Wuerzburg.NMOSD is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The company believes that the AIM Biologicals will present a specific antigen derived from the water channel protein aquaporin-4 loaded to soluble immunoregulatory HLA-G protein to selectively induce immunological tolerance in the central nervous system ((CNS)).Under the terms of the exclusive patent license agreement entered into with the University, Aeterna made an up-front cash payment of €100k and will pay milestone-based payments as well as royalty payments on net sales.Aeterna will be responsible for the formal preclinical and clinical development, regulatory activities, and manufacturing of the licensed products. Aeterna has also engaged the

For further details see:

Aeterna Zentaris in-licenses targeted immunosuppressive therapeutics for rare CNS disorder